LGALS3 and neoplasm: In a subset of lung and pancreatic adenocarcinomas addicted to mutant KRAS, the disruption of galectin-3/β3 interaction by GCS-100, a galectin-3 antagonist currently under clinical development [117], released mutant KRAS from β3 and inhibited tumor growth in mice.